

**Effects of Adenosine Receptor Agonists of the A₁, A_{2A} and
A₃ Subtypes on the Proinflammatory Activity of Human
Neutrophils *In Vitro***

by

Susanna Salomina Visser

Submitted in fulfilment of the requirements for the degree of
Doctor of Philosophy

In


The Department of Immunology
Faculty of Health Sciences
University of Pretoria

April 2002

Declaration

To my knowledge the work contained in this thesis is original, was undertaken by myself with occasional assistance as indicated in the acknowledgements. The interpretation and analysis of data were my primary responsibilities.

It is being submitted for the degree of Doctor of Philosophy at the University of Pretoria. It has not been submitted before for any degree or examination at any other university.

Signed: 

Date : 2002-06-26

Publications

Part of this thesis have been published in the following papers:

1. Visser SS, Theron AJ, Ramafi G, Ker JA & Anderson R. Apparent involvement of the A_{2A} subtype adenosine receptor in the anti-inflammatory interactions of CGS 21680, cyclopentyladenosine, and IB-MECA with human neutrophils. *Biochemical Pharmacology* 2000;60:993-999.
2. Anderson R, Visser SS, Ramafi G & Theron AJ. Accelerated resequestration of cytosolic calcium and suppression of the pro-inflammatory activities of human neutrophils by CGS 21680 *in vitro*. *British Journal of Pharmacology* 2000;130:717-724.

Summary

The apparent insensitivity of neutrophils to the anti-inflammatory effects of corticosteroids underscores the requirement for identifying agents which suppress neutrophil-driven inflammation. In a preliminary study, I was unable to demonstrate an inhibitory effect of glucocorticoids (dexamethasone) on the rapidly-activatable pro-inflammatory functions (superoxide production and elastase release) of human neutrophils activated with FMLP.

My subsequent research was directed at identifying the adenosine receptor (AR) subtypes which down-regulate the pro-inflammatory activities of human neutrophils, as well as the involvement of adenosine 3',5'-cyclic monophosphate (cAMP) and its relationship to cellular handling of Ca^{2+} in mediating these effects. Neutrophils were treated with varying concentrations (0.01 – 1 μ M) of AR agonists operative at A_1 (N^6 -cyclopentyladenosine, CPA), A_{2A} (2(4-[(2-carboxyethyl)phenyl]ethylamino)-5'-N-ethylcarboxamidoadenosine, CGS 21680), and A_3 (N^6 -(3-iodobenzyl-5'-N-methylcarbamoyl)adenosine, IB-MECA) receptors, after which they were activated with the chemoattractant, N-formyl-L-methionyl-L-leucyl-L-phenylalanine (FMLP, 1 μ M). Intracellular cAMP, superoxide production, and elastase release were assayed using radioimmunoassay, lucigenin-enhanced chemiluminescence (LECL), and colorimetric procedures, respectively, while changes in the concentrations of cytosolic Ca^{2+} were monitored by fura-2-based spectrofluorimetry. CGS 21680, at all concentrations tested, inhibited superoxide production in a dose-related manner, while CPA and IB-MECA were effective only at the highest concentrations tested (0.5 – 1 μ M). The release of elastase from activated neutrophils was also inhibited by all three AR agonists, but was more sensitive to CGS 21680 and IB-MECA than was superoxide production. The inhibitory effects of all 3 agonists on superoxide production and elastase release were associated with accelerated clearance of Ca^{2+} from the cytosol of activated neutrophils, and were effectively neutralized by pretreatment of the cells with the highly selective $A_{2A}R$ antagonist, ZM 241385 (4-(2-[7-amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-yl amino]ethyl)phenol). Increased cAMP was detected in neutrophils treated with CGS 21680 and IB-MECA (1 μ M). These data support the involvement of the $A_{2A}R$ subtype in the suppression

of superoxide production and degranulation by activated human neutrophils, probably by cAMP-mediated alterations in Ca^{2+} handling.

The involvement of the $\text{A}_{2\text{A}}\text{R}$ subtype in regulating the pro-inflammatory activities of neutrophils as well as the biochemical mechanism thereof, were subsequently investigated. Cytosolic Ca^{2+} fluxes, measured by fura-2 spectrofluorimetry in combination with radiometric procedures which distinguish between net efflux and influx of the cation, in FMLP-activated neutrophils in the presence and absence of CGS 21680, were determined. Treatment of neutrophils with CGS 21680 did not affect the FMLP-activated release of Ca^{2+} from intracellular stores, but resulted in dose-related acceleration of the rate of decline in fura-2 fluorescence, as well as decreases in both efflux and store-operated influx of Ca^{2+} , compatible with enhancement of re-sequestration of the cation by the endo-membrane Ca^{2+} -ATPase. These effects on neutrophil Ca^{2+} handling were associated with increased intracellular cyclic AMP and with inhibition of oxidant production and release of elastase. In contrast, treatment of neutrophils with ZM 241385 (2.5 μM), prevented the transient increase in cyclic AMP in FMLP-activated neutrophils which was associated with delayed sequestration of incoming Ca^{2+} during store-operated influx. The CGS 21680-mediated reduction of Ca^{2+} efflux from FMLP-activated neutrophils was also antagonized by pretreatment of the cells with ZM 241385 (2.5 μM), as well as by thapsigargin (1 μM), an inhibitor of the endo-membrane Ca^{2+} -ATPase. ZM 241385 also neutralized the cyclic AMP-elevating and anti-inflammatory interactions of CGS 21680 with neutrophils.

In conclusion, my results are compatible with a role for the $\text{A}_{2\text{A}}\text{R}$ in regulating the pro-inflammatory activities of human neutrophils by promoting cyclic AMP-dependent sequestration of cytosolic Ca^{2+} .

Keywords:

Adenosine; $\text{A}_{2\text{A}}$ receptors; calcium; calcium influx; calcium efflux; CGS 21680; CPA; cyclic AMP; dexamethasone; elastase; IB-MECA; neutrophils; superoxide; ZM 241385.

Samevatting

Die klaarblyklike ongevoeligheid van neutrofiele vir die anti-inflammatoriese effekte van kortikosteroïde beklemtoon die behoefte om agense te identifiseer wat neutrofiel-gedrewe inflammasie onderdruk. Ek was nie in staat om in 'n voorafgaande studie 'n onderdrukkende effek van glukokortikoïde op die snel-aktiveerbare pro-inflammatoriese funksies (superoksied produksie en elastase vrystelling) van menslike neutrofiele wat geaktiveer was met FMLP, aan te toon nie.

My daaropvolgende navorsing was gemik op identifisering van die adenosien reseptor (AR) subtypes wat die pro-inflammatoriese aktiwiteite van menslike neutrofiele af-reguleer, asook die betrokkenheid van adenosien 3',5'-sikliese monofosfaat (sAMF) en sy verhouding tot sellulêre hantering van Ca^{2+} in die bemiddeling van hierdie effekte. Neutrofiele is behandel met verskillende konsentrasies (0.01 – 1 μ M) van AR agoniste wat werksaam is op A_1 (N^6 -cyclopentyladenosine, CPA), A_{2A} (2(4-[(2-carboxyethyl) phenyl]ethylamino)-5'-N-ethylcarboxamidoadenosine, CGS 21680), en A_3 (N^6 -93-iodobenzyl-5'-N-methylcarbamoyladenosine, IB-MECA) reseptore, waarna hulle aktiveer is met die chemolokmiddel, N-formyl-L-methionyl-L-leucyl-L-phenylalanine (FMLP, 1 μ M). Intracellulêre sAMF, superoksied produksie, en elastase vrystelling is bepaal met radio-immuunbepaling, lucigenin-versterkte chemiluminessensie (LECL), en kolorimetriese prosedures, respektiewelik, terwyl veranderinge in die konsentrasies van sitosoliese Ca^{2+} moniteer is met fura-2-baseerde spektrofluorimetrie. CGS 21680, het by alle konsentrasies getoets, superoksied produksie inhibeer op 'n dosis-afhanklike wyse, terwyl CPA en IB-MECA slegs effektief was in die hoogste konsentrasies getoets (0.5-1 μ M). Die vrystelling van elastase vanaf geaktiveerde neutrofiele is ook inhibeer deur al drie AR agoniste, maar was meer gevoelig vir CGS 21680 en IB-MECA as wat superoksied produksie was. Die inhibitoriese effekte van al drie agoniste op superoksied produksie en elastase vrystelling het gepaard gegaan met versnelde opruiming van Ca^{2+} vanaf die sitosol van geaktiveerde neutrofiele, en was doeltreffend neutraliseer deur vooraf behandeling van die selle met die hoogs selektiewe A_{2A} antagonis, ZM 241385 (4-(2-[7-amino-2-(2-furyl) [1,2,4] triazolo [2,3-a] [1,3,5] triazin-5yl amino] ethyl) phenol). Verhoogde sAMF is gevind in

neutrofiële wat behandel was met CGS 21680 en IB-MECA ($1 \mu\text{M}$). Hierdie bevindings ondersteun die betrokkenheid van die $A_{2A}R$ sub tipe in die onderdrukking van superoksied produksie en degranulasie van geaktiveerde neutrofiële, waarskynlik via sAMF-bemiddelde veranderinge in Ca^{2+} hantering.

Die betrokkenheid van die $A_{2A}R$ sub tipe in die regulering van die pro-inflammatoriese aktiwiteite van neutrofiële asook die biochemiese meganisme daarvan, is vervolgens ondersoek. Sitosoliese Ca^{2+} vloeïings, bepaal met fura-2 spektrofluorimetrie in kombinasie met radiometriese bepalinge wat onderskei tussen netto uitvloeïing en invloeïing van die kation, is bepaal in FMLP-geaktiveerde neutrofiële in die teenwoordigheid en afwesigheid van CGS 21680. Behandeling van neutrofiële met CGS 21680 het nie die FMLP-geaktiveerde vrystelling van Ca^{2+} vanaf intrasellulêre store beïnvloed nie, maar het gelei tot dosis-verwante versnelling van die tempo van afname in fura-2 fluoressensie, asook afname in beide uitvloeïing en stoor-beheerde invloeïing van Ca^{2+} , verenigbaar met versterking van hersekwestrasie van die kation deur die endomembraan Ca^{2+} -ATPase. Hierdie effekte op neutrofiel Ca^{2+} hantering het gepaard gegaan met verhoogde intrasellulêre sikliese AMF en met inhibisie van oksidant produksie en vrystelling van elastase. In teenstelling, behandeling van neutrofiële met die selektiewe $A_{2A}R$ antagonis, ZM 241385 ($2.5 \mu\text{M}$), het die verbygaande styging in sikliese AMF in FMLP-geaktiveerde neutrofiële voorkom en het gepaard gegaan met vertraagde sekwestrasie van inkomende Ca^{2+} tydens stoor-beheerde invloeïing. Die CGS 21680-bemiddelde vermindering van Ca^{2+} uitvloeïing vanaf FMLP-geaktiveerde neutrofiële is ook teengewerk deur vooraf-behandeling van die selle met ZM 241385 ($2.5 \mu\text{M}$), asook deur thapsigargin ($1 \mu\text{M}$), 'n inhibitor van die endomembraan Ca^{2+} -ATPase. ZM 241385 het ook die sikliese AMF-verhogende en anti-inflammatoriese interaksies van CGS 21680 met neutrofiële geneutraliseer.

Ten slotte is my resutate verenigbaar met 'n rol vir die $A_{2A}R$ in die regulering van die pro-inflammatoriese aktiwiteite van menslike neutrofiële deur bevordering van sikliese AMF-afhanklike sekwestrasie van sitosoliese Ca^{2+} .

Sleutelwoorde:

Adenosien; A_{2A} reseptore; kalsium; kalsium invloei; kalsium uitvloei; CGS 21680; CPA; dexamethasone; elastase; IB-MECA; neutrofiel; superoksied; sikliese AMP; ZM 241385.

Acknowledgements

I want to express my gratitude to the following people for their assistance with the laboratory research and preparation of this thesis:

My supervisor, Professor Ronald Anderson, Head, Department of Immunology, University of Pretoria, who gave me the opportunity to do this research, inspired me throughout the duration and generously gave of his expertise and time.

My co-supervisor, Professor Annette Theron, Department of Immunology, University of Pretoria, for her guidance, encouragement and support.

Professor James Ker, Department of Internal Medicine, University of Pretoria, who made it possible for me to do the research at the Department of Immunology.

Ms Riana Cockeran for her assistance with the laboratory work (IL-8 measurement).

Dr Grace Ramafi for her assistance with the laboratory work (cAMP determination).

Ms Martie Madgwick for her valuable assistance in the preparation of this manuscript.

The friendly and always helpful librarians, Ms Myleen Oosthuizen and Ms Martie van der Walt, for assisting me in the preparation of the literature study.

Table of Contents

Summary	iv
Samevatting	vi
Acknowledgements	ix
Table of Contents	x
List of Figures	xiv
List of Tables	xvi
List of Abbreviations	xix
Chapter 1: Introduction and Literature Review	1
1.1 Introduction	2
1.2 Literature Review	2
1.2.1 Origins of human neutrophils	2
1.2.2 Neutrophil granules	5
1.3 Neutrophil Functions	8
1.3.1 Extravasation and chemotaxis	10
1.3.2 Adherence to vascular endothelium	10
1.3.3 Tethering and rolling	10
1.3.4 Firm adhesion	12
1.3.5 Transendothelial migration	13
1.3.6 Migration of neutrophils within interstitial tissues	13
1.4 Antimicrobial Mechanisms of Neutrophils	14
1.4.1 NADPH oxidase	14
1.4.2 Nitric oxide synthase	20
1.4.3 Cytokine production by neutrophils	21
1.5 Phospholipase A₂-Derived Mediators of Inflammation	24
1.6 Calcium Fluxes and Restoration of Calcium Homeostasis in Activated Neutrophils	25
1.6.1 Release of calcium from stores	25
1.6.2 Restoration of calcium homeostasis	26
1.7 Anti-Inflammatory Actions of cAMP	28
1.7.1 Cyclic AMP and neutrophils	28

1.8	Neutrophil-Directed, Anti-Inflammatory Chemotherapeutic Strategies	29
1.8.1	Corticosteroids	30
1.8.2	Limitations of corticosteroids	32
1.8.3	Neutrophils and corticosteroids	33
1.9	Adenosine and Neutrophils	39
1.9.1	Adenosine effects on neutrophil function	39
1.9.2	Adenosine and polypeptide mediators of inflammation	43
1.9.3	Adenosine receptors (ARs)	43
1.10	Hypothesis	48
1.11	Objectives	48
 Chapter 2: Effects of Dexamethasone on the Early- and Late-Activatable Pro-Inflammatory Functions of Human Neutrophils		 49
2.1	Introduction	50
2.2	Materials and Methods	51
2.2.1	Chemicals and reagents	51
2.2.2	Neutrophils	51
2.2.3	Oxidant generation	51
2.2.4	Elastase release	53
2.2.5	Interleukin-8 production by neutrophils	54
2.2.6	Statistical analysis	54
2.3	Results	55
2.3.1	Effects of dexamethasone on superoxide production by neutrophils	55
2.3.2	Effects of dexamethasone on the release of elastase by neutrophils	55
2.3.3	Effects of dexamethasone on the release of IL-8 from unstimulated and FMLP-activated neutrophils	55
2.4	Discussion	57
 Chapter 3: Apparent Involvement of the A_{2A} Subtype Adenosine Receptor in the Anti-Inflammatory Interactions of CGS 21680, Cyclopentyladenosine and IB-MECA with Human Neutrophils		 61
3.1	Introduction	61

3.2	Materials and Methods	63
3.2.1	Adenosine receptor agonists	63
3.2.2	Neutrophils	64
3.2.3	Oxidant generation	64
3.2.4	Elastase release	65
3.2.5	Intracellular cAMP levels	65
3.2.6	Spectrofluorimetric measurement of Ca ²⁺ fluxes	66
3.2.7	IL-8 production	66
3.2.8	Statistical analysis	67
3.3	Results	67
3.3.1	Oxidant production	67
3.3.2	Elastase release	68
3.3.3	CAMP	71
3.3.4	Fura-2 fluorescence	73
3.3.5	IL-8 production	76
3.4	Discussion	77
 Chapter 4: Accelerated Resequestration of Cytosolic Calcium and Suppression of the Pro-Inflammatory Activities of Human Neutrophils by CGS 21680 <i>In Vitro</i>		80
4.1	Introduction	81
4.2	Materials and Methods	82
4.2.1	Drugs and reagents	82
4.2.2	Neutrophils	82
4.2.3	Spectrofluorimetric measurement of Ca ²⁺ fluxes	83
4.2.4	Mn ²⁺ quenching of fura-2 fluorescence	83
4.2.5	Radiometric assessment of Ca ²⁺ fluxes	84
4.2.6	Efflux of ⁴⁵ Ca ²⁺ from FMLP-activated neutrophils	84
4.2.7	Influx of ⁴⁵ Ca ²⁺ into FMLP-activated neutrophils	85
4.2.8	Oxidant generation	85
4.2.9	Elastase release	86
4.2.10	Intracellular cAMP levels	86
4.2.11	Statistical analysis	87
4.3	Results	87
4.3.1	Fura-2 fluorescence responses of FMLP-activated neutrophils	87
4.3.2	Influx of Ca ²⁺ using Mn ²⁺ quenching of fura-2 fluorescence	92
4.3.3	Efflux of ⁴⁵ Ca ²⁺ from FMLP-activated neutrophils	92
4.3.4	Influx of ⁴⁵ Ca ²⁺ into FMLP-activated neutrophils	96
4.3.5	Superoxide generation and elastase release	96
4.3.6	Intracellular cAMP	100

4.4 Discussion	101
Chapter 5: Concluding Comments	106
Chapter 6: References	111

List of Figures

	Page
Figure 3.1: The effects of varying concentrations of CGS 21680, CPA and IB-MECA on the production of superoxide by FMLP-activated neutrophils.	69
Figure 3.2: The effects of varying concentrations of CGS 21680, CPA, and IB-MECA on the release of elastase from FMLP/CB-activated neutrophils.	72
Figure 3.3: FMLP-activated fura-2 responses of neutrophils with and without CGS 21680, CPA, or IB-MECA (all at 1 μ M).	74
Figure 4.1: FMLP-activated fura-2 fluorescence responses of control and CGS 21680 (1 μ M)-treated neutrophils.	88
Figure 4.2: FMLP (1 μ M)-activated fura-2 fluorescence responses of control and ZM 241385 (2.5 μ M)-treated neutrophils.	91
Figure 4.3: FMLP (1 μ M)-activated Mn^{2+} quenching of the fura-2 responses of control and CGS 21680 (1 μ M)-treated neutrophils	93
Figure 4.4: Kinetics of efflux of $^{45}Ca^{2+}$ out of unstimulated neutrophils and neutrophils activated with FMLP (1 μ M) in the absence and presence of CGS 21680 (1 μ M).	94
Figure 4.5: Kinetics of influx of $^{45}Ca^{2+}$ into unstimulated neutrophils and neutrophils activated with FMLP (1 μ M) in the absence and presence of CGS 21680 (1 μ M).	97

Figure 4.6: The effects of varying concentrations of CGS 21680 (0.01-1 μM) on superoxide production by FMLP (0.1 μM)-activated neutrophils and on elastase release from FMLP/CB-activated neutrophils. 98

List of Tables

	Page
Table 1.1: Constituents of neutrophil primary and secondary granules	7
Table 1.2: Constituents of neutrophil tertiary granules and secretory vesicles	9
Table 1.3: Cytokines expressed by neutrophils	22
Table 1.4: Agents which trigger cytokine production by neutrophils	23
Table 1.5: Anti-Inflammatory agents which are currently used or are under investigation for the treatment of asthma	30
Table 1.6: Summary of reports on the effects of corticosteroids on early-activatable neutrophil functions <i>in vitro</i>	34
Table 1.7: Summary of reports on the effects of corticosteroids on early-activatable neutrophil functions <i>in vivo</i>	37
Table 2.1: The effects of dexamethasone 1.25, 2.5, 5 and 10 μ M on superoxide generation by FMLP-activated neutrophils	56
Table 2.2: The effects of dexamethasone 10 μ M on superoxide production by PMA activated neutrophils	56
Table 2.3: Superoxide production by the hypoxanthine (1 mM)-xanthine oxidase (18 milliunits/ml) system in the presence and absence of dexamethasone	57
Table 2.4: The effects of dexamethasone on release of elastase from FMLP/CB-activated neutrophils	57

Table 2.5:	The effects of dexamethasone on the spontaneous and FMLP-activated synthesis of IL-8	58
Table 3.1:	The effects of ZM 241385 on CGS 21680-, CPA-, and IB-MECA-mediated inhibition of neutrophil superoxide generation and elastase release.	70
Table 3.2:	The effects of low concentrations (0.1 and 0.25 μ M) of ZM 241385 on CGS 21680-, CPA-, and IB-MECA-mediated inhibition of neutrophil superoxide production.	70
Table 3.3:	The effects of CGS 21680 and IB-MECA individually and in combination with ZM 241385 on cAMP in unstimulated and FMLP-activated neutrophils.	72
Table 3.4:	Peak intracellular calcium concentrations $[Ca^{2+}]_i$ and time taken for these to decline to half peak values in FMLP-activated neutrophils treated with the adenosine receptor agonists.	75
Table 3.5:	The effects of ZM 241385 on peak intracellular calcium concentrations $[Ca^{2+}]_i$ and time taken for these to decline to half peak values in FMLP-activated neutrophils with and without the adenosine receptor agonists.	75
Table 3.6:	The effect of CGS (1 μ M) on IL-8 production by unactivated and FMLP-activated human neutrophils.	76
Table 4.1:	Effects of CGS 21680 on peak cytosolic calcium concentrations ($[Ca^{2+}]_i$) and rates of clearance (half peak values) in FMLP-activated neutrophils.	90
Table 4.2:	Effects of CGS 21680 \pm ZM 241385 on peak intracellular calcium concentrations $[Ca^{2+}]_i$ and rates of clearance in FMLP-activated neutrophils.	90

Table 4.3:	Effects of varying concentrations of CGS 21680 on the efflux of $^{45}\text{Ca}^{2+}$ out of FMLP-activated neutrophils.	95
Table 4.4:	Effects of thapsigargin and ZM 241385 on the CGS 21680-mediated reduction in efflux of $^{45}\text{Ca}^{2+}$ out of FMLP-activated neutrophils.	95
Table 4.5:	Effects of thapsigargin and ZM 241385 on CGS 21680-mediated inhibition of superoxide production by, and elastase release from activated neutrophils.	99
Table 4.6:	The effects of CGS 21680 and ZM 241385 individually and in combination on cAMP levels in unstimulated and FMLP-activated neutrophils.	100

List of Abbreviations

A	adenosine
AA	arachidonic acid
A1	member of family of apoptotic regulators
A ₁ R	adenosine-1 receptor
A _{2A} R	adenosine-2A receptor
A _{2B} R	adenosine-2B receptor
A ₃ R	adenosine –3 receptor
ADP	adenosine diphosphate
AMP	adenosine monophosphate
ANCA	anti-neutrophil cytoplasmic antibody
ANOVA	analysis of variance
AP-1	activator protein-1
Apo1	apoptosis receptor-1
AR	adenosine receptor
ARDS	adult respiratory distress syndrome
ARF	ADP-ribosylation factor
ATP	adenosine triphosphate
AV	atrio-ventricular
BH1,2	anti-apoptotic regions in the Mcl-1 gene
BH3	pro-apoptotic region in the Mcl-1 gene
BPI	Bactericidal permeability increasing protein
C	Complement
cAMP	adenosine 3',5'-cyclic monophosphate
([Ca ²⁺] _i)	cytosolic free Ca ²⁺
CB	cytochalasin B
CBP	CREB binding protein
CD30L	CD30 ligand
Ced-9	Caenorhabditis elegans cell death gene
cGMP	cyclic guanosine monophosphate

CGS 21680	2(4-[(2-carboxyethyl)phenyl]ethylamino)-5'-N-ethylcarboxamidoadenosine
CINC	cytokine-induced chemoattractants
COX2	cyclooxygenase 2
CPA	N ⁶ -cyclopentyladenosine
cPLA ₂	cytosolic phospholipase A ₂
CREB	cyclic AMP response element binding factor
DMA	N,N-dimethylacetamide
DMSO	dimethyl sulphoxide
DNA	deoxyribonucleic acid
EP receptor	Prostaglandin E receptor
FAD	flavine-adenine-dinucleotide
Fas	CD 95 or Apo1
FasL	Fas ligand
FMLP	N-formyl-L-methionyl-L-leucyl-L-phenylalanine
FURA-2/AM	1-[2-(5-carboxyoxazol-2-yl)-6-aminobenzofuran-5-oxyl] -2-(2'-amino-5'-methylphenoxy)-ethane-N,N,N',N',-tetraacetic acid-acetoxy methylester oil
GC	glucocorticoid
G-CSF	granulocyte-colony stimulating factor
GDP	guanosine diphosphate
GM-CSF	Granulocyte macrophage-colony stimulating factor
gp91 ^{phox}	glycoprotein phagocyte oxidase, 91 kDa molecular weight.
GR	glucocorticoid receptor
GRE	glucocorticoid response element
GRO- α	growth-related gene product-alpha
GRO- β	growth-related gene product-beta
GTP	guanosine triphosphate
HAT	histone acyltransferase
HBSS	Hanks' balanced salt solution
HCl	hydrochloric acid
HGF	hepatocyte growth factor
HNP1,2,3	human neutrophil peptides 1,2 and 3

H ₂ O ₂	hydrogen peroxide
HOCl	hypochlorous acid
Hsp	heat shock protein
IB-MECA	N ⁶ -3-iodobenzyl-5'-N-methylcarbamoyladenine
ICAM	intercellular adhesion molecule
IFN-γ	interferon-gamma
IFN-β	interferon-beta
Iκ-B-α	inhibitor protein-kappa B-alpha
IL	interleukin
IL-1Ra	interleukin-1 receptor antagonist
iNOS	inducible nitric oxide synthase
JAM	junctional adhesion molecule
kDa	kiloDalton
LECL	lucigenin-enhanced chemiluminescence
LPC	lysophosphatidylcholine
LPS	lipopolysaccharide
LTB ₄	leukotriene B ₄
LTC ₄	leukotriene C ₄
LTD ₄	leukotriene D ₄
LTE ₄	leukotriene E ₄
MAPK	mitogen-activated protein kinase
Mcl-1	myeloid cell leukaemia gene product, member of family of apoptotic regulators
Mcl-1S/Δ TM	isoform of Mcl-1 with pro-apoptotic characteristics
MCP-1,2,3	monocyte chemotactic protein-1,2,3
M-CSF	macrophage-colony stimulating factor
MIP-1α	macrophage infiltrating protein-1alpha
MIP-1β	macrophage infiltrating protein-1beta
MnCl ₂	Manganese chloride
MPO	myeloperoxidase
mRNA	messenger RNA

NADPH	nicotinamide adenine dinucleotide phosphate (reduced form)
NADP	nicotinamide adenine dinucleotide phosphate
NECA	5'-N-ethylcarboxamidoadenosine
NF- κ B	nuclear factor-kappa B
nGRE	negative glucocorticoid response element
NO	nitric oxide
NSF	N-ethylmaleimide-sensitive fusion
O ₂ ⁻	superoxide anion
•OH	hydroxyl radical
OSM	oncostatin
p300	300 kDa polypeptide
PAF	platelet-activating factor
PAPA-APEC	2-[4-[2-[2-[phenylmethylcarbonylamino]ethylaminocarbonyl]ethyl]phenyl]ethylamino-5'-N-ethyl-carboxamidoadenosine
PBS	phosphate-buffered saline
PDE	phosphodiesterase
PECAM	platelet endothelial cell adhesion molecule
PGE ₂	prostaglandin E ₂
PKA	protein kinase A
PKC	protein kinase C
PLA ₂	phospholipase A ₂
PLC	phospholipase C
PMA	phorbol-12-myristate 13- acetate
PMN	polymorphonuclear leucocyte
P22 ^{phox}	protein/polypeptide phagocyte oxidase, 22 kDa molecular weight
P40 ^{phox}	protein/polypeptide phagocyte oxidase, 40 kDa molecular weight
P47 ^{phox}	protein/polypeptide phagocyte oxidase, 47 kDa molecular weight
P67 ^{phox}	protein/polypeptide phagocyte oxidase, 67 kDa molecular weight

Rac2	ribosome-associated complex, a member of the Ras superfamily
Raf	a serine kinase linking Ras activation with the nucleus
RANTES	“regulated on activation, normal T-cell expressed and secreted” chemokine
Rap1A	a member of the Ras superfamily
Ras	rat sarcoma gene product, a superfamily of GTP-binding proteins
Rho	a family of G-proteins
RNA	ribonucleic acid
SCF	stem cell factor
SEM	standard error of the mean
SNARES	soluble N-ethylmaleimide-sensitive fusion factor attachment protein receptor
SNAP-23	synaptosomal-associated protein of 23 kDa.
STATs	signal transducers and activators of transcription
STZ	serum-treated zymosan
TGF- α , β	tumour growth factor-alpha, beta
TNF- α	Tumour necrosis factor-alpha
TPA	12-O-tetradecanoylphorbol-13-acetate
t-SNARES	target plasma membrane protein-SNARES
VCAM	vascular cell adhesion molecule
VEGF	vascular endothelial growth factor
VLA-2,5,6,9	very late activation protein-2,5,6,9
v-SNARES	vesicle proteins-SNARES
ZM 241385	4-(2-[7-amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5yl amino]ethyl)phenol